Navigation Links
REMICADE-Treated Patients Experienced Rapid and Substantial Improvement in Psoriasis in Critical Regions of Body
Date:2/4/2008

indings presented by investigators, in each of the three psoriasis clinical trials evaluated, the Study of Psoriasis with Infliximab [REMICADE] Induction Therapy (SPIRIT), the European Infliximab for Psoriasis [REMICADE] Efficacy and Safety Study (EXPRESS), and the Evaluation of Infliximab for Psoriasis in a [REMICADE] Efficacy and Safety Study (EXPRESS II), a substantial proportion of REMICADE-treated patients experienced dramatic improvements in head- and neck-related psoriasis, trunk psoriasis and psoriasis of the lower and upper extremities as compared with the placebo group. Additionally, the improvements in each body region were generally consistent with the overall PASI response. At week 10, the proportions of patients achieving at least a 75 percent improvement or at least a 90 percent improvement of head- and neck-related psoriasis in the combined REMICADE groups (3 mg/kg and 5 mg/kg) versus placebo were as follows: SPIRIT, 86 percent versus 22 percent achieved at least 75 percent improvement and 69 percent versus 12 percent achieved at least 90 percent improvement; EXPRESS, 85 percent versus 13 percent achieved at least 75 percent improvement and 73 percent versus 8 percent achieved at least 90 percent improvement; EXPRESS II, 79 percent versus 10 percent achieved at least 75 percent improvement and 67 percent versus 6 percent achieved at least 90 percent improvement.

PASI responses for trunk psoriasis in the combined REMICADE groups (3 mg/kg and 5 mg/kg) versus placebo were as follows: SPIRIT, 86 percent versus 12 percent achieved at least 75 percent improvement and 66 percent versus 4 percent achieved at least 90 percent improvement; EXPRESS, 87 percent versus 5 percent achieved at least 75 percent improvement and 72 percent versus 1 percent achieved at least 90 percent improvement; EXPRESS II, 79 percent versus 7 percent achieved at least 75 percent improvement and 59 percent versus 4 percent achieved at least 90 percent improvement.

Patie
'/>"/>

SOURCE Centocor, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Observational Data Show Transfusion Patterns in Chemotherapy-Induced Anemia Patients Receiving Erythropoiesis-Stimulating Agents
2. TargeGen Announces Initiation of Clinical Trial of JAK2 Inhibitor TG101348 in Myeloproliferative Disease Patients
3. JAK2 Inhibitor Shows Potent Activity in Cells From MPD Patients
4. Tigris Pharmaceuticals Initiates Phase I Study of AFP-464 in Patients with Solid Tumors
5. Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical Trial of Bavituximab in Patients with Advanced Breast Cancer
6. Catalyst Pharmaceutical Partners Begins Enrollment for Its U.S. Phase II Clinical Trial of CPP-109 in Patients with Cocaine Addiction
7. Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
8. Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
9. Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent
10. Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation (ASCT) Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkins Lymphoma
11. Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... YORK , Sept. 17, 2014  Levi & ... in connection with possible claims of breaches of fiduciary ... To get more information, click here: ... you. If you own common stock in ... please contact Eduard Korsinsky, Esq. either via ...
(Date:9/17/2014)... , Sept. 17, 2014 /PRNewswire-iReach/ -- ... white paper discussing improvements in the development ... structures for both normal and diseased tissue ... information, simplifies surgical procedures, lowers surgical costs ... surgical procedures. The clinical ...
(Date:9/17/2014)... , Sept. 17, 2014 Bronstein, Gewirtz & ... purchasers of the securities of PDL BioPharma, Inc. ("PDL ... -News).  Such investors are advised to contact Peretz ... Kimelman at info@bgandg.com or 212-697-6484. ... certain of its executives violated federal securities laws. ...
Breaking Medicine Technology:Patient Outcomes Improve When Molecular Chemical Imaging Technology Is Used to Aid Robotic Surgical Procedures, According to New White Paper 2Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Investigates claims on behalf of Investors of PDL BioPharma, Inc. --PDLI 2
(Date:9/17/2014)... 17, 2014 In its latest blog post, ... believes that having family close by during a stay in ... the process is successful, is highlighting a member of the ... the lives of addicts across the country and around the ... can reduce the blood pressure, heart rate, and stress levels ...
(Date:9/17/2014)... sound like the ideas of a science fiction ... an exciting new approach to imaging local and ... prostate cancer, scientists at Virginia Commonwealth University Massey ... Johns Hopkins Medical Institutions have provided proof-of-principle of ... doctors, ability to see tumors that have metastasized ...
(Date:9/17/2014)... NY (PRWEB) September 17, 2014 In ... acknowledges that “bi-weekly telephonic discovery conferences would be beneficial ... such conferences through mid-December. “At the end of December,” ... assess the need for additional conferences. , “The ... recognizes that there is still much to be discussed ...
(Date:9/17/2014)... Dennis Thompson HealthDay Reporter ... in the womb to household chemicals known as phthalates ... Columbia University researchers reported in a new study. ... developing asthma between age 5 and 11 if their ... two phthalates (pronounced thal-ates), the researchers found. The two ...
(Date:9/17/2014)... The Scripps Research Institute (TSRI) have devised a ... effective against vancomycin-resistant strains of MRSA and other ... to have not one but two distinct mechanisms ... evolve resistance quickly. , "This is the prototype ... in clinical use a generation or maybe even ...
Breaking Medicine News(10 mins):Health News:Latest Best Drug Rehabilitation Blog Post Highlights How Dogs are Helping Addicts Recover 2Health News:New non-invasive technique could revolutionize the imaging of metastatic cancer 2Health News:New non-invasive technique could revolutionize the imaging of metastatic cancer 3Health News:Transvaginal Mesh Lawsuit News: New Order in C.R. Bard MDL Sets Schedule of Conferences for September to December, the Rottenstein Law Group LLP Reports 2Health News:Prenatal Exposure to Chemicals in Plastics Linked to Asthma Risk in Kids 2Health News:Prenatal Exposure to Chemicals in Plastics Linked to Asthma Risk in Kids 3Health News:Prenatal Exposure to Chemicals in Plastics Linked to Asthma Risk in Kids 4Health News:Scripps Research Institute chemists modify antibiotic to vanquish resistant bacteria 2Health News:Scripps Research Institute chemists modify antibiotic to vanquish resistant bacteria 3
... tend to outlive males, a circumstance that is usually ... especially when they compete for females. This might also ... higher parasite burden than females. Therefore, high variability of ... be more important for males. Scientists at the Research ...
... tests should not be used to predict Alzheimer,s disease, the ... Although there is a link between the two, ... their sense of smell, and it may not necessarily mean ... "A nonspecific association between poor smell function and Alzheimer,s ...
... THURSDAY, May 10 (HealthDay News) -- A new weight-loss ... and Drug Administration showed promising results in a recent ... a combination of the drugs phentermine and topiramate, experienced ... health problems, the study found. The findings were reported ...
... privately insured colon cancer patients found that managed care presence ... surgery to treat colon cancer lowered costs, a national team ... University School of Public Health and Health Services reported in ... cancer is the second leading cause of cancer death in ...
... from systemic sclerosis, also known as scleroderma, than Caucasians. ... a journal of the American College of Rheumatology (ACR), ... likely to have antibodies that increased frequency and severity ... According to the ACR there are 49,000 ...
... Chronic exposure to cocaine reduces the expression of a ... in vivo research on the molecular basis of cocaine ... which produce greater sensitivity to the rewarding effects of ... for development of a treatment for cocaine addiction. It ...
Cached Medicine News:Health News:Living longer - variability in infection-fighting genes can be a boon for male survival 2Health News:Smell Tests Don't Predict Alzheimer's, Study Finds 2Health News:New Weight-Loss Drug Shows Promise in Trial 2Health News:New Weight-Loss Drug Shows Promise in Trial 3Health News:Economic theory actually works in health care 2Health News:Systemic sclerosis complications more severe in African Americans than Caucasians 2Health News:Chronic cocaine use triggers changes in brain's neuron structure 2
The Eppendorf Maxipettor is a continuously adjustable pipette for precise pipetting of volumes up to 10 ml (in 10 l increments). Even liquids with a high vapor pressure or viscosity can be pipetted w...
... The Repeater Plus, a handheld manual ... saving time on long series pipetting. Its ... exceptional support for research tasks, and its ... with repetitive work. The nine Combitips allow ...
eValuator fixed-curve diagnostic electrophysiology catheters offer an effective balance between clinical performance and cost....
The True Non-Compliant Balloon....
Medicine Products: